Ranolazine Prevents Heart Failure with Preserved Ejection Fraction; Diastolic Dysfunction and Left Ventricular Hypertrophy in a Hypertensive Murine Model

2011 ◽  
Vol 17 (8) ◽  
pp. S13
Author(s):  
R. Valadri ◽  
R. Gadesam ◽  
A. Onwuanyi ◽  
M.T. Fan ◽  
H. Bloom
Keyword(s):  
Heart Failure ◽  
Left Ventricular Hypertrophy ◽  
Ejection Fraction ◽  
Diastolic Dysfunction ◽  
Murine Model ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Preserved Ejection Fraction

scholarly journals Cardiac Remodeling Biomarkers as Potential Circulating Markers of Left Ventricular Hypertrophy in Heart Failure with Preserved Ejection Fraction

2020 ◽  
Vol 250 (4) ◽  
pp. 233-242
Author(s):  
Valentina T. Mitic ◽  
Dijana R. Stojanovic ◽  
Marina Z. Deljanin Ilic ◽  
Miodrag M. Stojanovic ◽  
Dejan B. Petrovic ◽  
...  
Keyword(s):  
Heart Failure ◽  
Left Ventricular Hypertrophy ◽  
Ejection Fraction ◽  
Cardiac Remodeling ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Preserved Ejection Fraction ◽  
Circulating Markers

scholarly journals Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?

2020 ◽  
Vol 6 ◽  
Author(s):  
Sebastiaan HC Klaassen ◽  
Dirk J van Veldhuisen ◽  
Hans LA Nienhuis ◽  
Maarten P van den Berg ◽  
Bouke PC Hazenberg ◽  
...  
Keyword(s):  
Heart Failure ◽  
Left Ventricular Hypertrophy ◽  
Ejection Fraction ◽  
Ventricular Hypertrophy ◽  
Treatment Options ◽  
High Sensitivity ◽  
Left Ventricular ◽  
Clinical Suspicion ◽  
Preserved Ejection Fraction ◽  
Attr Amyloidosis

Heart failure with preserved ejection fraction (HFpEF) comprises half of the heart failure population. A specific, but underdiagnosed, cause for HFpEF is transthyretin-derived (ATTR) amyloidosis. This article reviews the clinical characteristics of cardiac ATTR amyloidosis. The clinical suspicion of cardiac ATTR amyloidosis is strong if pronounced left ventricular hypertrophy is present in the absence of hypertension. Scintigraphy with a diphosphonate tracer is a diagnostic tool for the early detection of cardiac ATTR amyloidosis with high sensitivity and specificity. First treatment options for ATTR amyloidosis recently emerged, and showed a reduction in morbidity and mortality, especially if treatment was started in the early stages of disease. In light of these results, screening for ATTR amyloidosis in the general HFpEF population with left ventricular hypertrophy might be useful.

Sign in / Sign up

Export Citation Format

Share Document